The feasibility study represents a first step toward a potential collaboration focused on dedicated R&D and regulatory proceedings and future supply of Egoo Health systems for the targeted application.

While the pharmaceutical partner remains undisclosed at this stage, the collaboration is anchored in a defined clinical and commercial use case where decentralized, high quality biomarker measurement is viewed as strategically important.

"This feasibility program is designed to answer the technical and integration questions required to move into a long-term development and supply collaboration. Our partner has a clear strategic interest in this application, and the structure of the project reflects that ambition." said Thomas Warthoe, CEO of Qlife.

Strengthening Qlife's partner driven growth model

This announcement underscores Qlife's continued strategic focus on partner-led development, where global pharmaceutical and diagnostics companies leverage the Egoo platform as a scalable backbone for biomarker-driven therapeutic applications.

The Company is increasingly focusing its R&D investments on co-development models that:

• Reduce time from feasibility to deployment
• Enable application-specific optimisation
• Support long-term supply and lifecycle collaboration

This approach allows Qlife to concentrate resources on programs with clear commercial pull and defined downstream economics.

Qlife will provide further updates as key milestones are achieved.